SGMO
Sangamo BioSciences, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Aug. 26, 2013, 4:19 PM
    • Sangamo BioSciences (SGMO) will acquire privately held Ceregene which specializes in AAV gene therapies.
    • The deal gives SGMO CERE-110, a Phase 2 investigational Alzheimer's drug that contains the gene for nerve growth factor. Results are expected in 2015. (PR)
    | Aug. 26, 2013, 4:19 PM